Emerging therapeutic agents in the treatment of relapsed or refractory diffuse large B cell lymphoma
Canadian Hematology Today · 2022
DOI: 10.58931/cht.2022.1110 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Hematology Today, 2022. Verfasst von Anthea Peters. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
Diffuse large B cell lymphoma (DLBCL) is the most common type of aggressive non-Hodgkin lymphoma (NHL). The median age at diagnosis of DLBCL is 65, and about one-third of patients are older than age 75 at diagnosis. The standard of care for frontline treatment is chemoimmunotherapy, consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP). Approximately 60% of patients are cured with standard treatment, but it is inaccessible for up to 25% of patients due to advanced age and underlying comorbidities, including cardiac dysfunction. Several biologic factors confer risk of treatment failure, including activated B cell (ABC) cell of origin and double expressor phenotype (i.e. and overexpression of c-MYC and BCL2).
Zitieren
APA
Peters, A. (2022). Emerging therapeutic agents in the treatment of relapsed or refractory diffuse large B cell lymphoma. Canadian Hematology Today. https://doi.org/10.58931/cht.2022.1110
Vancouver
Peters A. Emerging therapeutic agents in the treatment of relapsed or refractory diffuse large B cell lymphoma. Canadian Hematology Today. 2022. doi:10.58931/cht.2022.1110
BibTeX
@article{Peters2022,
author = {Peters, Anthea},
title = {Emerging therapeutic agents in the treatment of relapsed or refractory diffuse large B cell lymphoma},
journal = {Canadian Hematology Today},
year = {2022},
doi = {10.58931/cht.2022.1110}
}
EUVIMED